AZTAAZTAHealthcare · Medical Instruments & Supplies

AZTA Stock Forecast: Azenta, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$45
−4.86% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 96 of 100 as at 21 Nov 2026 — among the strongest tenth.

Market cap
$2.0B
Ticker Nerd rank
96/ 100
Median analyst target
$52
Analysts covering
—
Revenue$161.2M+12.0% y/y
Operating income−$3.7M
Net income$2.5M
Free cash flow−$3.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.9%
1M
+25.4%
YTD
+34.7%
1Y
+49.3%
From 52W high
−8.4%
From 52W low
+179.7%
$16
$49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Azenta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
96/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Value
89
Issuance
85
Revisions
82
Quality
77
Momentum
74
Volatility
72
Growth
42

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (42): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AZTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AZTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26AZTAHigh $57Median $52Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
11 Nov 2026JefferiesMaintainsBuy$44 → $52
11 Nov 2026NeedhamMaintainsBuy$37 → $57
14 Sept 2026NeedhamReiteratesBuy$37
6 Aug 2026Evercore ISI GroupMaintainsOutperform$28 → $35
5 Aug 2026NeedhamMaintainsBuy$33 → $37
6 May 2026NeedhamMaintainsBuy$44 → $33
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
17 Mar 2026NeedhamReiteratesBuy—
5 Feb 2026Evercore ISI GroupMaintainsOutperform—
4 Feb 2026JefferiesMaintainsBuy—
4 Feb 2026NeedhamReiteratesBuy—
8 Jan 2026TD CowenMaintainsHold—
5 Jan 2026Evercore ISI GroupUpgradeOutperform—
19 Dec 2025NeedhamMaintainsBuy—
25 Nov 2025Raymond JamesMaintainsOutperform—
21 Nov 2025NeedhamMaintainsBuy—
30 Oct 2025JefferiesUpgradeBuy—
6 Aug 2025Raymond JamesUpgradeOutperform—
5 Aug 2025Evercore ISI GroupMaintainsIn-Line—
8 July 2025Evercore ISI GroupMaintainsIn-Line—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AZTA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AZTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Azenta, Inc. returned +49.3% against +6.9% for the S&P 500, dividends included.

AZTA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26AZTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AZTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−19.1%
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.0×

Cheaper than 37% of US stocks

Price / book
1.3×

Cheaper than 59% of US stocks

EV / EBITDA
46.8×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
44.9%

Higher than 56% of US stocks

Operating margin
−3.3%

Higher than 31% of US stocks

Net margin
—
Returns & dividend
Return on equity
−10.1%

Higher than 37% of US stocks

Return on assets
−0.7%

Higher than 41% of US stocks

Dividend yield
0.9%

Higher than 17% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Azenta, Inc. has a market value of $2.0B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $613.6M. The latest quarter grew 12.0% year on year.

  • Net income over the same four quarters: −$122.9M, a −20.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.76.

  • Free cash flow in the twelve months to 30 June 2026: $9.9M.

  • Shares outstanding: 43.8M.

  • forward P/E: 50.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.89%.

  • Azenta, Inc. employs 2,900 people — $212K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

AZTA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
AZTAAzenta, Inc.$2.0B96
LMATLeMaitre Vascular, Inc.$1.7B69
XRAYDentsply Sirona, Inc.$1.7B78
KMTSKestra Medical Technologies Ltd.$1.4B27
ATRCAtriCure, Inc.$2.8B94
WRBYWarby Parker, Inc.$2.9B28
STAASTAAR Surgical Co.$1.2B89

Take a look at AZTA’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Azenta, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AZTA

How does Ticker Nerd's model rank AZTA?

As at 21 Nov 2026, Azenta, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

What is the AZTA stock forecast for 2030?

No analyst covering Azenta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $57 over the next 12 months.

How has AZTA stock performed over the past year?

Azenta, Inc. returned +49.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Azenta, Inc. do?

Azenta, Inc. is a life sciences tools and services company focused on sample management, biostorage, and genomic services. The company provides automated storage systems, temperature-controlled logistics, laboratory consumables, informatics, and repository services that help customers preserve, track, and manage biological and chemical samples across research, clinical development, and commercialization workflows.

Company

About Azenta, Inc.

Azenta, Inc. is a life sciences tools and services company focused on sample management, biostorage, and genomic services. The company provides automated storage systems, temperature-controlled logistics, laboratory consumables, informatics, and repository services that help customers preserve, track, and manage biological and chemical samples across research, clinical development, and commercialization workflows. Azenta also offers sequencing, gene synthesis, and related multiomics services for pharmaceutical, biotechnology, academic, and healthcare customers. Its solutions are used to support drug development, clinical research, advanced therapies, and biospecimen handling, making the company an important provider of infrastructure for sample integrity and data-driven life sciences operations. Azenta is headquartered in Burlington, Massachusetts, and serves a global customer base across North America, Europe, and Asia.

CEO Dr. Martin D. Madaus D.V.M., Ph.D. · 2,900 employees · United States · https://www.azenta.com